Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents.

Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Abstract Text:

Stephen N Davis,Don Johns,David Maggs,Hangtao Xu,Justin H Northrup,Robert G Brodows,Stephen N Davis,Don Johns,David Maggs,Hangtao Xu,Justin H Northrup,Robert G Brodows,Stephen N Davis,Don Johns,David Maggs,Hangtao Xu,Justin H Northrup,Robert G Brodows,

OBJECTIVE: This 16-week study explored the safety of substituting exenatide for insulin in patients with type 2 diabetes using insulin in combination with oral antidiabetes agents. RESEARCH DESIGN AND METHODS: Successful maintenance of glycemic control was predefined as an A1C increase of < 0.5%. A total of 49 patients (aged 53 +/- 8 years, with BMI 34 +/- 4 kg/m2, A1C 8.1 +/- 1.1%, and duration of diabetes 11 +/- 7 years) were randomized to either substitute exenatide for insulin or remain on their current insulin regimen. Patients who either completed > or = 8 weeks of study or discontinued because of loss of glycemic control were included in primary efficacy analysis. RESULTS: A total of 62% (18 of 29) of the exenatide-treated patients maintained glycemic control compared with 81% (13 of 16) of the insulin-treated patients. Of the 11 exenatide-treated patients who did not maintain control, 5 discontinued before week 16 because of loss of glucose control. The overall safety profile was generally consistent with previous exenatide trials. The mean overall hypoglycemia rates were 1.72 and 0.97 events/patient-year for the exenatide and insulin reference groups, respectively. CONCLUSIONS: This pilot study suggests that it is feasible to sustain glycemic control when substituting exenatide for insulin. Although it is not possible to characterize clear predictors of outcome given the size and exploratory nature of the study, the data suggest that patients with longer disease duration, who are taking higher doses of insulin and have less endogenous beta-cell function, may experience deterioration in glucose control if exenatide is substituted for insulin therapy.

Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Publishing Authors By Initials

SN Davis,D Johns,D Maggs,H Xu,JH Northrup,RG Brodows,SN Davis,D Johns,D Maggs,H Xu,JH Northrup,RG Brodows,SN Davis,D Johns,D Maggs,H Xu,JH Northrup,RG Brodows,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Journal Published:

PUBLICATION TYPE: Multicenter Study

Journal: Diabetes care

VOLUME: 30

Page Numbers: 2767-72

Journal Abbreviation: Diabetes Care

ISSN: 1935-5548

DAY: 26

MONTH: 06

YEAR: 2007

Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7805975

Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents.

AFFILIATION: Endocrinology and Metabolism, Vanderbilt University, 715 PRB, 2220 Pierce Ave., Nashville, TN 37232-6303, USA. steve.davis@vanderbilt.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Diabetes Care

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents Related Publications

• Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study.
• Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents.
• Nursing homes as acute care providers. A pilot study of incentives to reduce hospitalizations.
• The ACCESS process: assuring quality in long term care.